31 results about "Acute myelogenous leukemia (AML)" patented technology

Belonging to the field of pharmaceutical compounds, the invention relates to 11, 20-dicarbonyl Jiyuan rubescensin a and L-amino acid-14-ester trifluoroacetate thereof, and a preparation method and usethereof. The preparation method includes: adopting Jiyuan rubescensin a as the raw material and performing oxidation with a Jones reagent, thus obtaining 11, 20-dicarbonyl Jiyuan rubescensin a, the structure of which is shown as the specification; then carrying out 14-position esterification reaction with N-BOC-L-amino acid to obtain N-BOC-L-amino acid-11, 20-dicarbonyl Jiyuan rubescensin a ester(III), then removing BOC protective group in trifluoroacetic acid, and then conducting salt forming to obtain L-amino acid-14-(11, 20-dicarbonyl Jiyuan rubescensin a)ester trifluoroacetate, which hasthe following general formula. The compound has good stability and anti-tumor activity, and provides the basis for screening antitumor drugs against esophageal cancer, gastric cancer, primary liver cancer, pancreatic cancer, cardiac carcinoma, colorectal cancer, bladder cancer, breast cancer, acute myelogenous leukemia and the like.

The invention discloses a chimeric antigen receptor and a gene and a recombinant expression vector thereof, an engineered CD33 targeting NKT cell and an application thereof. The chimeric antigen receptor is CD33ScFv-CD8-CD137-CD3zeta which is formed by connecting CD33ScFv, a hinge domain and a transmembrane domain of CD8, an intracellular signal structural domain of CD137 and an intracellular signal structural domain of CD3zeta in series. By adopting the chimeric antigen receptor CD33ScFv-CD8-CD137-CD3zeta modified NKT cell for treating CD33 positive acute myelogenous leukemia in a progressive stage, drug resistance and chemotherapy resistance caused by combined application of a CD33 monoclonal antibody and chemotherapy can be effectively avoided, and the cell has specific killing activity on leukemia cells.

The invention relates to a micro ribonucleic acid (miRNA) marker group related to acute myelogenous leukemia, and a specific primer and application of the miRNA marker group. The marker group is composed of a miR-23b-3p marker and a miR-26a-5p marker, wherein a nucleotide sequence of the miR-23b-3p marker is as shown in SEQ ID NO.1, and the nucleotide sequence of the miR-26a-5p marker is as shown in SEQ ID NO.2. The invention also relates to a specific primer and application of the miRNA marker group. Two markers screened by the micro ribonucleic acids (microRNAs) marker group provided by the invention are strong in complementarity. Thus, the detection is quantitative and accurate, and the sensibility and the specificity of disease diagnosis are greatly improved.

The invention provides a CLL1 and CD33 double-target chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain, and the antigen binding domain comprises an anti-CLL1 single-chain antibody and an anti-CD33 single-chain antibody. According to the constructed CAR molecule simultaneously targeting CLL1 and CD33, the effect of comprehensively targeting acute myelogenous leukemia cells is achieved, the CAR-T cells for expressing CLL1 and CD33 double-target CAR are remarkable in tumor removal effect, the antigen escape phenomenon is avoided, and the CAR molecule has important significance in the field of tumor treatment.

The invention particularly relates to application of METTL3 in AML chemotherapy drug resistance, and belongs to the technical field of molecular biology and medicine. The clinical treatment effect of AML is poor, the prognosis condition is poor, and relapse and refractory cases cannot be relieved through conventional therapy. The invention provides a molecular marker for detecting the chemotherapy sensitivity of acute myelogenous leukemia by analyzing the expression difference of METTL3 in bone marrow of a patient relatively sensitive to AML chemotherapy and a patient resistant to AML chemotherapy. Through AML chemotherapy sensitive cell strains, chemotherapy drug-resistant cell strains and animal models, the AML chemotherapy drug-resistant treatment effect of the METTL3 inhibitor is proved. The research of the invention also proves that METTL3 can mediate AML chemotherapy resistance by regulating AML cell homing.

The invention provides a combined pharmaceutical composition for treating acute myelogenous leukemia and application of the combined pharmaceutical composition. The combined pharmaceutical composition for treating acute myelogenous leukemia comprises chidamide and apatinib. According to the combined medicine composition, the medicine chidamide and the medicine apatinib are creatively combined to serve as a medicine for treating acute myelogenous leukemia, and the research shows that the combined chidamide and apatinib have the effect of more remarkably inhibiting AML cell proliferation compared with single chidamide or apatinib; has the effect of more remarkably inducing AML cell apoptos compared with single chidamide or apatinib, and has the effect of more remarkably prolonging the survival time of an AML mouse model compared with single chidamide or apatinib. The combined pharmaceutical composition provides a new strategy and thought for the treatment of acute myelogenous leukemia, and has very significant significance.

The invention provides a compound with a structure as shown in a general formula (I), a deuterated substance, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and application of the compound and the deuterated substance, the stereoisomer or the pharmaceutically acceptable salt. The compound provided by the invention has a good PIM kinase inhibition effect, is a novel, high-activity and low-toxicity ideal PIM inhibitor, can be used for treating and/or preventing diseases such as hematoma such as acute myelogenous leukemia, myelofibrosis and chronic lymphocytic leukemia, solid tumors such as gastric cancer and prostate cancer, and has a wide application prospect.

The invention belongs to the field of chimeric antigen recipient cells, and relates to a chimeric antigen recipient cell targeting human CD33 and NKG2DL as well as a preparation method and application thereof, and the chimeric antigen recipient cell contains amino acid sequences targeting binding human CD33 and targeting binding human NKG2DL. The immune response cell modified by the bispecific chimeric antigen receptor targeting CD33 and NKG2DL can enhance the combination with tumor cells, and has obvious anti-tumor activity in tumors expressing human CD33/NKG2DL antigens, such as acute myelogenous leukemia (AML).

The invention discloses an application of GNF-7 in preparation of an FLT3 mutant inhibitor. The GNF-7 provided by the invention can be in targeted combination with FLT3-ITD and F691L, overcomes drug-resistant mutation of F691L, achieves a better treatment effect on acute myelogenous leukemia compared with quinatinib AC220, and has a good application prospect.

The invention relates to the field of biological information, in particular to a method and system for completing karyotype analysis of a to-be-detected sample based on whole genome sequencing and a computer readable medium. The method for determining the predetermined chromosome variation of the to-be-detected sample replaces traditional karyotype analysis, second-generation sequencing and dynamic cutoff are combined, CNV large fragments can be rapidly and accurately detected, and meanwhile, according to the result, based on chromosome karyotype analysis, the detection accuracy of the CNV large fragments is greatly improved. Diseases (such as acute myelogenous leukemia and myelodysplastic syndrome) related to chromosome copy number variation can be detected, and treatment and prognosis can be guided. The detection method provided by the invention is high in sensitivity, lower in detection limit and more accurate in detection result, and can be used for prognosis of diseases related to chromosome copy number variation by annotating the position of the gene related to prognosis and the position of variation on the chromosome.

The invention provides a tumor screening kit based on blood analysis, and relates to the technical field of blood detection. The tumor screening kit based on blood analysis comprises a staining enhancement solution for enhancing the staining effect and a specific antibody with a fluorescent staining mark, and the staining enhancement solution is prepared from the following raw materials in percentage by mass: 1%-5% of a surfactant, 90%-94% of a biological buffer solution and 0.5%-0.8% of polyethylene glycol. The leukocyte and the residual erythrocyte can be removed at one time, the enrichment efficiency is higher, interference of other cells on fluorescent staining can be eliminated after enrichment treatment, better observation through a fluorescence microscope is facilitated, expression on the surfaces of most acute myelogenous leukemia cells is achieved, and the application prospect is wide. The targeted CD20 antibody is a bispecific antibody taking a red blood cell surface antigen CD3 and a white blood cell surface antigen CD20 as targets, adapts to the heterogeneity of cells, and avoids the condition of leak detection.

The invention relates to a novel FLT3 kinase inhibitor and synthesis and application thereof, the structural formula of the inhibitor is shown in the specification, wherein the R1, R2, R3 and R4 are respectively and independently one of H, C1-C10 alkyl, C1-C10 alkoxy or halogen. Compared with Quizartinib, the inhibitor synthesized by the invention has the advantages that the IC50 value is in the same order of magnitude or even lower than that of Quizartinib, and the inhibitor can be used for preparing medicines for treating acute myelogenous leukemia.